Loading asset research
Liminatus Pharma Inc. Class A Common Stock
LIMNNasdaq · USD · StocksQuote as of · Exchange session not verified$3.47
-4.41%
Today
LIMN
Loading 1D prices…
Market cap
$4.7M
Volume
31.4K
52w high
$141.5052w low
$3.42Company profile
Liminatus Pharma Inc. Class A Common Stock
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
Cerritos, CA, United States
Employees
1
Fiscal year end
1231
CIK
1971387
Session & valuation
Open$3.63
Previous close$3.63
Day high$3.67
Day low$3.46
30-day avg. volume447.1K
Outstanding shares67.2M
Diluted EPS-$0.43
Latest annual period
P/E (trailing)-8.07
P/E (forward)—
Price / book12.90
Beta0.71
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2836
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| PMCBPharmaCyte Biotech Inc. Common Stock | $4.8M | $0.00 | — | -$2.77 | +4.82% | Unrated |
| VIVSVivoSim Labs Inc. Common Stock | $3.8M | $131K | -10567.18% | -$5.35 | -6.67% | Unrated |
| CELZCreative Medical Technology Holdings Inc. Common Stock | $6.3M | $6K | -99916.80% | -$2.52 | +1.09% | Buy |
| CLDICalidi Biotherapeutics Inc. Common Stock | $3.2M | $0.00 | — | -$5.95 | -5.34% | Unrated |
| CRISCuris Inc. Common Stock | $2.7M | $9.4M | -80.29% | -$0.58 | -2.59% | Buy |